What one share of Syndax Pharmaceuticals holds
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.
Syndax Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.87 |
|---|---|
| Profit | −$2.51 |
| Cash and investments | $3.77 |
| Debt | $2.74 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.08 | −$3.22 | $0.02 | −$2.42 | — | $4.62 |
| 2017 | $0.10 | −$2.90 | $0.00 | −$2.26 | — | $4.28 |
| 2018 | $0.06 | −$2.92 | $0.01 | −$2.71 | — | $2.14 |
| 2019 | $0.05 | −$1.84 | — | — | — | $1.16 |
| 2020 | $0.04 | −$1.87 | $0.00 | −$1.73 | — | $5.27 |
| 2021 | $2.61 | $0.46 | $0.00 | $0.54 | — | $7.43 |
| 2022 | $0.00 | −$2.46 | $0.00 | −$2.20 | — | $6.86 |
| 2023 | $0.00 | −$2.98 | $0.00 | −$2.28 | — | $6.53 |
| 2024 | $0.28 | −$3.72 | $0.00 | −$3.21 | — | $3.36 |
| 2025 | $1.99 | −$3.29 | $0.00 | −$3.73 | — | $0.74 |
Common questions about Syndax Pharmaceuticals
How much does one share of Syndax Pharmaceuticals earn?
Over the last 12 months, Syndax Pharmaceuticals lost $2.51 for each share on $2.87 of sales.
Does Syndax Pharmaceuticals pay a dividend?
Syndax Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Syndax Pharmaceuticals’s book value per share?
Syndax Pharmaceuticals’s book value is $0.17 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Syndax Pharmaceuticals have?
Each share of Syndax Pharmaceuticals has $3.77 of cash and investments and $2.74 of debt, as of June 30, 2026.
Has Syndax Pharmaceuticals bought back shares?
Syndax Pharmaceuticals’s share count rose about 493% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.